PTX 4.65% 4.1¢ prescient therapeutics limited

CellPryme-M question, page-20

  1. 3,872 Posts.
    lightbulb Created with Sketch. 3205
    Thanks @hottod that was the most informative response on the topic so far, certainly matches up with what Steven has commentated on regulation wise...Steven would be well informed & keeps in constant communication with the FDA...He also has not tried to oversell CellPryme so I trust his information FDA wise.

    The Biden administration have come out & said they are going to pull out all stops on cancer.

    That means minor adjustments like CellPryme would only need submissions to FDA if at all, or what's the point?

    We are talking minor % changes to cell therapies involving our own cells, if complete trials over a decade were required every time an iteration or improvement is discovered the sector would be dead in the water.

    Forgetting licensing and royalties, CellPryme would have to be adding long term value for shareholders & increasing PTX profile as a potential takeover target.

    CellPryme is a big deal, both as a revenue stream long term but for our own in-house CAR-T programs...OmniCar was already the most exciting CAR-T program in the world in my opinion and it just got further turbo charged.

    Holy grail right there.
    Last edited by BigDaniel: 13/06/22
 
watchlist Created with Sketch. Add PTX (ASX) to my watchlist
(20min delay)
Last
4.1¢
Change
-0.002(4.65%)
Mkt cap ! $33.01M
Open High Low Value Volume
4.2¢ 4.3¢ 4.1¢ $7.846K 186.5K

Buyers (Bids)

No. Vol. Price($)
5 290288 4.1¢
 

Sellers (Offers)

Price($) Vol. No.
4.2¢ 3226 1
View Market Depth
Last trade - 16.10pm 08/11/2024 (20 minute delay) ?
PTX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.